Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.61 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR2B | P41595 | 4/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL184033 | 0.98 | PNMT (0.59) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL20909783 | 0.86 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL14992356 | 0.86 | HTR2A (0.54) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL22545196 | 0.86 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL31139061 | 0.86 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL27087829 | 0.86 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL29098022 | 0.86 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL20909780 | 0.86 | PNMT (0.52) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL107123 | 0.82 | PNMT (0.43) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL20571565 | 0.81 | HTR2C (0.59) | PNMTHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0040990-A1 | Antiallergic imidodisulfamides, their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1981-12-02 | — | — | EP | claimed |
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-109280030-B | Benzazaylalkyl aryl piperazine derivative and application thereof in preparing medicines | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-110483511-B | Synthetic method of quinazolinone polycyclic compound | 常州大学 | 2021-06-22 | — | — | CN | disclosed |
| US-20210015829-A1 | CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2021-01-21 | — | — | US | disclosed |
| CN-110483511-A | A kind of synthetic method of quinazolinone polycyclic compounds | UNIV CHANGZHOU | 2019-11-22 | — | — | CN | disclosed |
| CN-109280030-A | Benzene a pair of horses going side by side azepine alkylaryl bridged piperazine derivatives and application in medicine preparation | 江苏恩华药业股份有限公司 | 2019-01-29 | — | — | CN | disclosed |
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1697304-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| EP-1697304-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| US-4767862-A | ANIMAL ADRENERGIC BLOCKING AGENTS; CARDIOVASCULAR DISORDERS, HEADACHES, GLAUCOMA | SMITHKLINE BECKMAN CORPORATION (US) | 1988-08-30 | — | — | US | disclosed |
| US-4707485-A | Substituted te[1]trahydroisoquinoline derivatives having β-adrenergic receptor activity | SMITHKLINE BECKMAN CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0210827-A2 | Tetrahydroisoquinoline derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION (US) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | PNMT 2492/4885ASIC3 2793/4885HTR2A 1122/4885 |
| US-20210015829-A1 | CYCLIC TREX1 INHIBITORS | TMX1, TSNAX, TPX2 | PNMT 4196/4885ASIC3 1556/4885HTR2A 3214/4885 |
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | PNMT 323/4885ASIC3 1995/4885HTR2A 37/4885 |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PNMT 4249/4885ASIC3 4118/4885HTR2A 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.